Details for Patent: 5,753,706

Which drugs does patent 5,753,706 protect, and when does it expire?

Patent 5,753,706 protects AURYXIA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 5,753,706

Title:	Methods for treating renal failure
Abstract:	Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
Inventor(s):	Hsu; Chen Hsing (Ann Harbor, MI)
Assignee:
Application Number:	08/794,328
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 5,753,706

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014		RX	Yes	Yes			Y			CONTROL OF SERUM PHOSPHOROUS LEVELS

International Family Members for US Patent 5,753,706

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	400264
Australia	5441998
Australia	723091
Canada	2272711